Last reviewed · How we verify
HS-20093 in combination with Adebrelimab
At a glance
| Generic name | HS-20093 in combination with Adebrelimab |
|---|---|
| Sponsor | Shanghai Hansoh Biomedical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (PHASE3)
- Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (PHASE1)
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (PHASE1)
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: